Cynata Therapeutics to soon receive a patent in Japan

Australian biotechnology company specialising in cell therapy, Cynata Therapeutics Limited (ASX:CYP), has received a Decision to Grant a Patent from the Japanese Patent Office (JPO) for a patent application titled “Pluripotent Stem Cell Assay”.

When the patent office intends to issue a patent, the Decision to Grant a Patent is sent to the applicant (Cynata). The Company anticipates that the patent will be granted by March 2022, with an expiration date of November 15, 2037.

Last year, the Patent Office of the Russian Federation accepted Cynata’s two patent applications, granting two new patents covering its Cymerus™ technology.

Read More at Cynata (ASX:CYP) secures two new patents for its unique Cymerus™ technology

Significance of the new patent

The patent application is wholly owned by Cynata and covers the Company’s proprietary Cymerus mesenchymal stem cell (MSC) technology. The inventors named on the patent include Ms Diana Drier, Dr Derek Hei, and Professor Igor Slukvin - founder, advisor, and shareholder of Cynata.

Image Source: © Nkooume | Megapixl.com

Once granted, this patent will join a rapidly growing estate of issued patents covering Cynata’s Cymerus platform. The patent builds on broad IP protection of the Cymerus technology and its unique ability to produce highly consistent MSCs from a single donation at commercial scale, to create therapeutic stem cell products.

Must Read: A glance at Cynata’s near-term catalysts for growth

Management view

As per Cynata’s Chief Executive Officer, Dr Ross Macdonald, the latest patent describes a crucial analytical procedure to assure the uniformity and quality of Cynata’s Cymerus MSC products. The patent builds on the Company’s already comprehensive patent portfolio to protect its proprietary and unique IP.

According to Dr Macdonald, it is of particular relevance the patent will be granted in Japan, which is the leading country in regenerative medicine and the second-largest market for pharmaceutical products.

He further highlighted that the Cymerus platform enables the production of consistent, high-quality MSCs at scale. This valuable and unique characteristic of the Company’s technology is key to the development of off-the-shelf therapeutic stem cell products to target multiple devastating diseases across the globe.

Also read: Meet Cynata Therapeutics’ highly competent leadership team

Cynata’s shares closed the trading session at A$0.48 on 28 January 2021.